Mesoblast to Participate in Piper Sandler Healthcare Conference
I'm PortAI, I can summarize articles.
Mesoblast Limited announced its participation in the Piper Sandler 37th Annual Healthcare Conference in New York, where CEO Silviu Itescu will engage in a fireside chat. This highlights Mesoblast's strategic focus on expanding its innovative cellular therapies and maintaining industry positioning. The most recent analyst rating on Mesoblast stock is a Hold with a A$3.00 price target. Mesoblast is a leader in developing allogeneic cellular medicines for inflammatory diseases, with its flagship product Ryoncil approved for treating pediatric graft versus host disease.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments